SecBot SecBot
SECBOTREPLAY Home › Report › CRBU

CRBU · Caribou Biosciences reported longer follow-up data from the CaMMouflage…

Caribou Biosciences, Inc. · PRESS-RELEASE filed Jun 11, 2026 at 08:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 11, 2026 at 08:00 ET

Caribou Biosciences reported longer follow-up data from the CaMMouflage Phase 1 trial of CB-011, an off-the-shelf BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma. In the BCMA-naïve recommended dose expansion cohort (n=12), results showed a 92% ORR, 83% CR/≥CR rate, 91% MRD negativity, and 50% of patients sustaining ≥CR at 15 months, with a manageable safety profile. These data will be presented at EHA on June 14, 2026, and initial dose expansion data in both BCMA-naïve and BCMA-exposed patients are expected in H2 2026.

  • Single dose of CB-011 at the 450M cell RDE produced 92% ORR, 83% CR/≥CR rate, 91% MRD negativity in BCMA-naïve patients (n=12).
  • 50% of patients in the BCMA-naïve RDE cohort maintained ≥CR at 15 months; median follow-up 17.7 months.
  • A case study of a patient who had failed approved autologous CAR-T (cilta-cel) achieved CR by day 28 with CB-011.
  • Safety profile was manageable with no GvHD, parkinsonism, or cranial nerve palsies; one (8%) ≥Gr 3 CRS, no ≥Gr 3 ICANS at RDE.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access